OXFORD BioMedica, a leading gene and cell therapy company, has announced its intention to raise approximately £20.5m, through the issue of shares.
The net proceeds will be used to expand the company’s bioprocessing facilities.
John Dawson, Chief Executive Officer of Oxford BioMedica, said:
“Oxford BioMedica is at the centre of the gene and cell therapy revolution. The company already has partnerships based on revenues, milestones and royalties with Novartis and Orchard Therapeutics and we recently announced our latest agreement with Bioverativ. With the approval of the first approved gene therapy in the US, Novartis’ Kymriah, we have seen an increase in business development activity.”
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here